Biotech Values

[DewDiligence]

HSP gets EU approval for Neupogen biosimilar:

http://finance.yahoo.com/news/NivestimTM-a-New-Biosimilar-prnews-3089808046.html?x=0&.v=1

Biosimilars in the EU are essentially branded generics, i.e. they are non-substitutable for the original brand and they have to be actively marketed.

HSP’s Neupogen knockoff will be sold under the brand name, Nivestim. It will have to compete with several other Neupogen biosimilars as well as AMGN’s original product, so it probably won’t be a big moneymaker.